GNMSF
$354.71
Genmab A\/S Dkk
$.46
.13%
GNMSF
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Wednesday
Nov 4
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when GNMSF reports earnings?
Beat
Meet
Miss

Where is GNMSF's stock price going from here?
Up
Flat
Down
Stock chart of GNMSF
Analysts
Summary of analysts' recommendations for GNMSF
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.